Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Clinical trial NCT04686305 · RECRUITING
Trial details
- NCT number
- NCT04686305
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-09
- Primary completion
- 2027-06-30
- Enrollment
- 304
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.